LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence

Q4 Medicine

Transplantation Reports Pub Date : 2023-09-01 DOI:10.1016/j.tpr.2023.100139

Yvonne Schill , Mario Schiffer , Lars Pape

{"title":"LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence","authors":"Yvonne Schill , Mario Schiffer , Lars Pape","doi":"10.1016/j.tpr.2023.100139","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The new LCP-formulation of tacrolimus (Tac) has shown pharmacokinetic advantages in patients after liver transplantation that are associated with better adherence. The influence of prolonged release Tac on adherence, trough levels and dosing of Tac remains unclear.</p></div><div><h3>Methods</h3><p>A prospective study was performed in 62 patients from two centers, who were switched to LCP-Tac after kidney transplantation, to assess adherence as defined by the Tac trough level coefficient of variation (CoV) (primary endpoint) and BAASIS© Score, as well as kidney function, Tac trough level and tacrolimus dose.</p></div><div><h3>Results</h3><p>BAASIS© Score and Tac trough level CoV demonstrated good adherence over the study period, with no difference between the study timepoints (0.26 ± 0.16 at study start and 0.26 ± 0.11 at study end, <em>p</em> = 0.976, paired <em>t</em>-test). Graft function and Tac trough levels remained stable, and Tac dose could be reduced.</p></div><div><h3>Conclusions</h3><p>A switch to LCP-Tac is feasible and leads to stable adherence, graft function and Tac trough levels, in combination with lower Tac doses.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451959623000148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The new LCP-formulation of tacrolimus (Tac) has shown pharmacokinetic advantages in patients after liver transplantation that are associated with better adherence. The influence of prolonged release Tac on adherence, trough levels and dosing of Tac remains unclear.

Methods

A prospective study was performed in 62 patients from two centers, who were switched to LCP-Tac after kidney transplantation, to assess adherence as defined by the Tac trough level coefficient of variation (CoV) (primary endpoint) and BAASIS© Score, as well as kidney function, Tac trough level and tacrolimus dose.

Results

BAASIS© Score and Tac trough level CoV demonstrated good adherence over the study period, with no difference between the study timepoints (0.26 ± 0.16 at study start and 0.26 ± 0.11 at study end, p = 0.976, paired t-test). Graft function and Tac trough levels remained stable, and Tac dose could be reduced.

Conclusions

A switch to LCP-Tac is feasible and leads to stable adherence, graft function and Tac trough levels, in combination with lower Tac doses.

查看原文本刊更多论文

lcp -他克莫司在长期肾移植受体中的应用:剂量和依从性

新的lcp制剂他克莫司(Tac)在肝移植后患者中显示出药代动力学优势，并具有更好的依从性。缓释Tac对Tac依从性、波谷水平和剂量的影响尚不清楚。方法对来自两个中心的62例肾移植后改用LCP-Tac的患者进行前瞻性研究，以Tac谷水平变异系数(CoV)(主要终点)和BAASIS©评分、肾功能、Tac谷水平和他克莫司剂量来评估依从性。结果basasis©评分和Tac波谷水平CoV在研究期间表现出良好的依从性，研究时间点之间无差异(研究开始时为0.26±0.16，研究结束时为0.26±0.11,p = 0.976，配对t检验)。移植物功能和Tac谷底水平保持稳定，Tac剂量可以降低。结论采用LCP-Tac是可行的，结合较低的Tac剂量，可获得稳定的粘附性、移植物功能和Tac最低水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation Reports Medicine-Transplantation

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

101 days

期刊介绍： To provide to national and regional audiences experiences unique to them or confirming of broader concepts originating in large controlled trials. All aspects of organ, tissue and cell transplantation clinically and experimentally. Transplantation Reports will provide in-depth representation of emerging preclinical, impactful and clinical experiences. -Original basic or clinical science articles that represent initial limited experiences as preliminary reports. -Clinical trials of therapies previously well documented in large trials but now tested in limited, special, ethnic or clinically unique patient populations. -Case studies that confirm prior reports but have occurred in patients displaying unique clinical characteristics such as ethnicities or rarely associated co-morbidities. Transplantation Reports offers these benefits: -Fast and fair peer review -Rapid, article-based publication -Unrivalled visibility and exposure for your research -Immediate, free and permanent access to your paper on Science Direct -Immediately citable using the article DOI